Search (News)

Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed In Phase II Study Of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined With Ivonescimab In Breast Cancer

english top health

(MENAFN - PR Newswire) HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study ...
2026-08-10 00:16:09